Namida Lab Announces Poster Presentation at the 2022 San Antonio Breast Cancer Symposium

Namida Lab Announces Poster Presentation at the 2022 San Antonio Breast Cancer Symposium




Namida Lab Announces Poster Presentation at the 2022 San Antonio Breast Cancer Symposium

FAYETTEVILLE, Ark.–(BUSINESS WIRE)–Namida Lab, the world leader in tear-based diagnostics, today announced that key research and developmental work on tear-based breast cancer biomarkers was presented at the San Antonio Breast Cancer Symposium (SABCS) on December 9, 2022, in San Antonio, Texas. Research and Development Scientist and co-author, Dr. Prashanth Ravishankar, presented the work on behalf of Namida Lab.

The groundbreaking research included the most extensive published data set of individually analyzed tear samples and demonstrated the clinical feasibility of tear proteins to detect breast abnormalities, resulting in the launch of Auria™, a first-of-its-kind home breast health assessment test.

Backed by physicians and more than a decade of research and clinical trials, Auria™ is now available for women, ages 30-85, regardless of their breast tissue density, to encourage breast health screening, by identifying protein biomarkers related to breast abnormalities through the power of tears.

Details of the poster presentation are as follows:

Abstract Number: P6-03-07

Title: Development of an at-home breast health assessment test, to increase compliance with screening mammography using proteins from tears.

The San Antonio Breast Cancer Symposium is attended by a broad international audience from over 90 countries of academic and private physicians and researchers. Since 1977, the Symposium’s mission has been to provide state-of-the-art information on breast cancer research.

The inventor of Auria™, Dr. Anna Daily, an expert in protein biochemistry with numerous peer-reviewed publications and patents on tear-based diagnostic development said, “This technology has taken over a decade of research, development, and clinical studies made possible through collaborations with comprehensive breast health and cancer centers across the US. Prashanth presenting our work at such a notable forum like SABCS is truly an honor.”

The Auria™ at-home test provides a personalized score and classification which corresponds to a level of urgency on when to schedule a screening mammogram. Auria customers also have the unique opportunity to schedule a one-on-one consultation with a breast health specialist to review their test results and ask any questions they may have related to their overall breast health. The goal is to encourage women to take control of their breast health. Auria is available for purchase online at https://auria.care/.

About Namida Lab

Namida Lab Inc. is a product-stage biotechnology company specializing in the development and commercialization of proteomics tests. Namida operates a high complexity CLIA (Clinical Laboratory Improvement Amendments) certified lab in addition to a Research & Development Lab to create and validate screening and diagnostic tools utilizing the untapped power of tears. Focusing on the oncology space, covering screening and diagnostics, their team consists of prominent scientists and industry professionals to improve diagnostic testing and patient outcomes.

Contacts

Saul Robles

Senior Marketing Manager, Namida Lab, Inc.

+1-479-334-2828

saul@namidalab.com